Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 9Plasma cell 6Other hematologic neoplasm 5Genitourinary 3Tumor-Agnostic 2Thoracic 2Sarcoma 1Other 1Myeloid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Endometrial Neoplasms 1Cystadenocarcinoma, Serous 1

Interventions

Paclitaxel 233Carboplatin 217Bevacizumab 139Cisplatin 136pembrolizumab 89Gemcitabine 69olaparib 54Docetaxel 47Topotecan 44Radiotherapy 43liposomal doxorubicin 41Taxes 41niraparib 38Cyclophosphamide 36Doxorubicin 30Drug Therapy 29Letrozole 28Nivolumab 27Magnetic Resonance Spectroscopy 25Immunoglobulin G 25Disulfides 24Oxaliplatin 23Albumin-Bound Paclitaxel 23durvalumab 22apatinib 21Etoposide 21Brachytherapy 21lenvatinib 20camrelizumab 20Specimen Handling 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Diphenhydramine × Gynecologic × Clear all
NCT00515073 2014-07-03

Papillary Serous Carcinoma of the Endometrium

M.D. Anderson Cancer Center

Phase 2 Completed
30 enrolled 5 charts
Gynecologic

Endometrial Neoplasms, Cystadenocarcinoma, Serous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡